{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=91&state=Wisconsin", "query": { "state": "Wisconsin", "city": "Milwaukee", "page": 91 }, "page_size": 10 }, "pagination": { "page": 91, "page_size": 10, "total_count": 5353, "total_pages": 536, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=92&state=Wisconsin&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=90&state=Wisconsin&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T23:58:00.834Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01874353", "title": "Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Platinum Sensitive", "BRCA Mutated", "Relapsed Ovarian Cancer", "Following Complete or Partial Response to Platinum Based Chemotherapy" ], "interventions": [ { "name": "Olaparib 300mg tablets", "type": "DRUG" }, { "name": "Placebo to match olaparib 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 327, "start_date": "2013-09-03", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-11-06T23:58:00.834Z", "location_count": 16, "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01874353" }, { "nct_id": "NCT01192295", "title": "Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Oxycodone HCl controlled-release tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Purdue Pharma LP", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "6 Years to 16 Years" }, "enrollment_count": 155, "start_date": "2010-11", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2020-03-23", "last_synced_at": "2026-11-06T23:58:00.834Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192295" }, { "nct_id": "NCT03992456", "title": "Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Colon Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Rectal Cancer AJCC v8", "Stage IIIB Colon Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Colon Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Rectal Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8", "Unresectable Colon Adenocarcinoma", "Unresectable Colorectal Carcinoma", "Unresectable Rectal Adenocarcinoma" ], "interventions": [ { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-04-24", "completion_date": "2024-10-07", "has_results": true, "last_update_posted_date": "2024-05-21", "last_synced_at": "2026-11-06T23:58:00.834Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03992456" }, { "nct_id": "NCT01625156", "title": "Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Tivantinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2012-05", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2015-10-20", "last_synced_at": "2026-11-06T23:58:00.834Z", "location_count": 2, "location_summary": "Madison, Wisconsin • Milwaukee, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01625156" }, { "nct_id": "NCT03131453", "title": "A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alzheimers Disease" ], "interventions": [ { "name": "CNP520 50mg", "type": "DRUG" }, { "name": "CNP520 15mg", "type": "DRUG" }, { "name": "Matching placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "60 Years to 75 Years" }, "enrollment_count": 1145, "start_date": "2017-08-03", "completion_date": "2020-03-26", "has_results": true, "last_update_posted_date": "2021-08-05", "last_synced_at": "2026-11-06T23:58:00.834Z", "location_count": 95, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 83 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03131453" }, { "nct_id": "NCT01130272", "title": "Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Irritable Bowel Syndrome" ], "interventions": [ { "name": "Eluxadoline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Furiex Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 807, "start_date": "2010-04-28", "completion_date": "2011-07-14", "has_results": true, "last_update_posted_date": "2019-10-22", "last_synced_at": "2026-11-06T23:58:00.834Z", "location_count": 288, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 225 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01130272" }, { "nct_id": "NCT01732822", "title": "A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Peripheral Artery Disease" ], "interventions": [ { "name": "Ticagrelor", "type": "DRUG" }, { "name": "Clopidogrel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "50 Years to 130 Years" }, "enrollment_count": 13885, "start_date": "2012-12-04", "completion_date": "2016-09-26", "has_results": true, "last_update_posted_date": "2017-10-30", "last_synced_at": "2026-11-06T23:58:00.834Z", "location_count": 290, "location_summary": "Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 239 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Auburn", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01732822" }, { "nct_id": "NCT03428945", "title": "Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type1 Diabetes Mellitus" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 273, "start_date": "2018-08-15", "completion_date": "2022-10-31", "has_results": true, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-11-06T23:58:00.834Z", "location_count": 37, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 33 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03428945" }, { "nct_id": "NCT04718103", "title": "A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "GSK3511294", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 397, "start_date": "2021-02-04", "completion_date": "2024-04-11", "has_results": true, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-11-06T23:58:00.834Z", "location_count": 41, "location_summary": "Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Lancaster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04718103" }, { "nct_id": "NCT01349322", "title": "Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Standard fractionation whole breast irradiation", "type": "RADIATION" }, { "name": "Hypofractionated whole breast irradiation", "type": "RADIATION" }, { "name": "Concurrent boost", "type": "RADIATION" }, { "name": "Sequential boost", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 2354, "start_date": "2011-05-24", "completion_date": null, "has_results": true, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-11-06T23:58:00.834Z", "location_count": 386, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01349322" } ] }